<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERYC- erythromycinÂ capsule, coated pelletsÂ </strong><br>Warner Chilcott (US), LLC<br></p></div>
<h1>ERYC<span class="Sup">Â®Â </span><br>(Erythromycin Delayed-Release Capsules, USP)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_3CB30A2F-A64C-452B-B134-D6C3A10AFD8B"></a><a name="section-2"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERYC<span class="Sup">Â®</span> and other antibacterial drugs, ERYC should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_8653C654-A646-426E-8DB5-895DE7BF5127"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ERYC capsules contain enteric-coated pellets of erythromycin base for oral administration. Each ERYC capsule contains 250 mg of erythromycin base. Also contains: lactose NF, povidone USP, FD&amp;C Yellow #6 and other ingredients. The capsule shell contains gelatin NF, titanium dioxide USP, FD&amp;C Yellow #6.</p>
<p>Erythromycin is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Saccharopolyspora erythraea</span> (formerly <span class="Italics">Streptomyces erythraeus</span>) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids but it is the base which is microbiologically active. Erythromycin base is (3<span class="Italics">R</span> *, 4<span class="Italics">S</span> *, 5<span class="Italics">S</span> *, 6<span class="Italics">R</span> *, 7<span class="Italics">R</span> *, 9<span class="Italics">R</span> *, 11<span class="Italics">R</span> *, 12<span class="Italics">R</span> *, 13<span class="Italics">S</span> *, 14<span class="Italics">R</span> *)-4-[(2,6-Dideoxy-3-<span class="Italics">C</span>-methyl-3-<span class="Italics">O</span>-methyl-Î±-L-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-Î²-D-<span class="Italics">xylo</span>-hexopyranosyl]oxy]-oxacyclotetradecane-2,10-dione.</p>
<div class="Figure">
<img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=C3F7CD94-D842-4F6B-A582-A38C751A790A&amp;name=eryc-01.jpg"><p class="MultiMediaCaption">ERYTHROMYCIN</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_460722CA-1339-4903-B13B-7B247A980433"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve acceptable serum levels. Erythromycin is largely bound to plasma proteins, and the freely dissociating bound fraction after administration of erythromycin base represents 90% of the total erythromycin absorbed. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. The drug is excreted in human milk. The drug crosses the placental barrier, but fetal plasma levels are low. Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
<p>In the presence of normal hepatic function erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral administration, less than 5% of the administered dose can be recovered in the active form in the urine.</p>
<p>The enteric coating of pellets in ERYC capsules protects the erythromycin base from inactivation by gastric acidity. Because of their small size and enteric coating, the pellets readily pass intact from the stomach to the small intestine and dissolve efficiently to allow absorption of erythromycin in a uniform manner. After administration of a single dose of a 250 mg ERYC capsule, peak serum levels in the range of 1.13 to 1.68 mcg/mL are attained in approximately 3 hours and decline to 0.30 to 0.42 mcg/mL in 6 hours. Optimal conditions for stability in the presence of gastric secretion and for complete absorption are attained when Erythromycin is taken on an empty stomach.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E35BB8D5-92FB-4FDB-9A78-133B0CDE2A92"></a><a name="section-4.1"></a><p></p>
<h2>Microbiology: </h2>
<p class="First">Erythromycin acts by inhibition of protein synthesis by binding 50 <span class="Italics">S</span> ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated <span class="Italics">in vitro</span> between erythromycin and clindamycin, lincomycin, and chloramphenicol. </p>
<p>Many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Haemophilus influenzae</span> are resistant to erythromycin alone but are susceptible to erythromycin and sulfonamides used concomitantly. </p>
<p>Staphylococci resistant to erythromycin may emerge during a course of therapy.</p>
<p>Erythromycin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#i4i_indications_ID_37772C48-F39D-489D-BBD8-9934C167EEE8">INDICATIONS AND USAGE</a> section.</p>
<p>Gram-positive Organisms:</p>
<dl>
<dt>Â </dt>
<dd><span class="Italics">Corynebacterium diphtheriae</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Corynebacterium minutissimum</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Listeria monocytogenes</span></dd>
<dt>Â </dt>
<dd>
<span class="Italics">Staphylococcus aureus</span> (resistant organisms may emerge during treatment)</dd>
<dt>Â </dt>
<dd><span class="Italics">Streptococcus pneumoniae</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Streptococcus pyogenes</span></dd>
</dl>
<p>Gram-negative Organisms:</p>
<dl>
<dt>Â </dt>
<dd><span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></dd>
<dt>Â </dt>
<dd><span class="Italics">Haemophilus influenzae</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Legionella pneumophila</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Neisseria gonorrhoeae</span></dd>
</dl>
<p>Other Microorganisms:</p>
<dl>
<dt>Â </dt>
<dd><span class="Italics">Chlamydia trachomatis</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Entamoeba histolytica</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Mycoplasma pneumoniae</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Treponema pallidum</span></dd>
<dt>Â </dt>
<dd><span class="Italics">Ureaplasma urealyticum</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E4199726-EDE5-4B53-830C-75246111551A"></a><a name="section-4.2"></a><p></p>
<h2>Susceptibility Tests:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_3F1A1BD5-11AD-4412-9CF3-A158B3F12088"></a><a name="section-4.2.1"></a><p></p>
<h3><span class="Underline">Dilution techniques:</span></h3>
<p class="First">Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICâ€™s). These MICâ€™s provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICâ€™s should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of erythromycin powder. The MIC values should be interpreted according to the following criteria:</p>
<a name="ID_7389B343-68E9-4553-A905-92A0FA61F784"></a><table frame="void" width="370.8">
<col width="48.544%">
<col width="51.456%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top"><span class="Underline">MIC (Î¼g/mL)</span></td>
<td class="Toprule" align="center" valign="top"><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td align="center" valign="top">â‰¤ 0.5</td>
<td align="center" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="center" valign="top">1 - 4</td>
<td align="center" valign="top">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">â‰¥ 8</td>
<td align="center" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard erythromycin powder should provide the following MIC values:</p>
<a name="ID_D10C9445-63B5-4A71-AA35-1C7C774E1C23"></a><table frame="void" width="370.8">
<col width="48.544%">
<col width="51.456%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top"><span class="Underline">Microorganism</span></td>
<td class="Toprule" align="center" valign="top"><span class="Underline">MIC (Î¼g/mL)</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">
<span class="Italics">S. aureus</span> ATCC 29213</td>
<td align="center" valign="top">0.12 - 0.5</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_23A3E65F-F514-4E86-8A34-BE60B9AA2066"></a><a name="section-4.2.2"></a><p></p>
<h3><span class="Underline">Diffusion techniques:</span></h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15 Î¼g erythromycin to test the susceptibility of microorganisms to erythromycin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 15 Î¼g erythromycin disk should be interpreted according to the following criteria:</p>
<a name="ID_9446E833-E14B-4230-95A9-BE08AE727569"></a><table frame="void" width="370.8">
<col width="48.544%">
<col width="51.456%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top"><span class="Underline">Zone diameter (mm)</span></td>
<td class="Toprule" align="center" valign="top"><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td align="center" valign="top">â‰¥ 23</td>
<td align="center" valign="top">Susceptible (S)</td>
</tr>
<tr>
<td align="center" valign="top">14 - 22</td>
<td align="center" valign="top">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">â‰¤ 13</td>
<td align="center" valign="top">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for erythromycin.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 15 Î¼g erythromycin disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<p>Â </p>
<a name="ID_7CFA1BBF-5BA8-4971-920D-C5DAD04948B5"></a><table frame="void" width="370.8">
<col width="48.544%">
<col width="51.456%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="top"><span class="Underline">Microorganism</span></td>
<td class="Toprule" align="center" valign="top"><span class="Underline">Zone Diameter (mm)</span></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">
<span class="Italics">S. aureus</span> ATCC 25923</td>
<td align="center" valign="top">22 - 30</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_37772C48-F39D-489D-BBD8-9934C167EEE8"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Erythromycin is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the diseases listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span> of mild to moderate degree caused <span class="Italics">by Streptococcus pyogenes, Streptococcus pneumoniae</span>, or <span class="Italics">Haemophilus influenzae</span> (when used concomitantly with adequate doses of sulfonamides, since many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information).</p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> of mild to moderate severity caused by <span class="Italics">Streptococcus pneumoniae</span> or <span class="Italics">Streptococcus pyogenes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> caused by <span class="Italics">Listeria monocytogenes</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> (whooping <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>) caused by <span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span>. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> in exposed susceptible individuals.</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> due to <span class="Italics">Mycoplasma pneumoniae</span>.</p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mild to moderate severity caused by <span class="Italics">Streptococcus pyogenes</span> or <span class="Italics">Staphylococcus aureus</span> (resistant staphylococci may emerge during treatment). </p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> due to <span class="Italics">Corynebacterium diphtheriae</span>, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.</p>
<p>Erythrasma: In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Corynebacterium minutissimum</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by <span class="Italics">Treponema pallidum</span>: Erythromycin is an alternate choice of treatment for primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> in penicillin-allergic patients. In primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.</p>
<p>Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> caused by <span class="Italics">Entamoeba histolytica</span> (oral erythromycins only). Extraenteric <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> requires treatment with other agents.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">Neisseria gonorrhoeae</span>: Erythromycin lactobionate for injection, USP followed by erythromycin base orally, as an alternative drug in treatment of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by <span class="Italics">N. gonorrhoeae</span> in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> before receiving erythromycin as treatment of <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> and a follow-up serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> after 3 months.</p>
<p>Erythromycins are indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Chlamydia trachomatis</span>: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> of the newborn, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> of infancy, and urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults due to <span class="Italics">Chlamydia trachomatis</span>.</p>
<p>When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.</p>
<p>Legionnairesâ€™ Disease caused by <span class="Italics">Legionella pneumophila</span>. Although no controlled clinical efficacy studies have been conducted, <span class="Italics">in vitro</span> and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnairesâ€™ Disease.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E4F99C58-97C6-48F9-B69F-28560FB24D76"></a><a name="section-5.1"></a><p></p>
<h2>Prophylaxis:</h2>
<p class="First">Prevention of Initial Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>: Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> (treatment of <span class="Italics">Streptococcus pyogenes</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the upper respiratory tract, e.g., <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Erythromycin is indicated for the treatment of penicillin-allergic patients.<span class="Sup">3</span> The therapeutic dose should be administered for ten days.</p>
<p>Prevention of Recurrent Attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>: Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span> (for the prevention of recurrent attacks of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>).<span class="Sup">3</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERYC and other antibacterial drugs, ERYC should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_8793A843-1AA9-46D9-AF02-BAABEFF94047"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Erythromycin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this antibiotic.</p>
<p>Erythromycin is contraindicated in patients taking terfenadine or astemizole. (See <span class="Bold"><a href="#i4i_precautions_ID_52303DD9-D5E6-447F-87D3-AC5F0F3A46CB">PRECAUTIONS</a> -<a href="#i4i_drug_interaction_ID_E000AEB4-6C1D-4D6E-8EE6-8F478273BA97">Drug Interactions: </a></span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_EB0A3363-9545-4795-8993-D9B0ECDA79CA"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">There have been reports of prolonged QT syndrome in geriatric patients receiving oral erythromycin products.</p>
<p>There have been reports of hepatic dysfunction, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, occurring in patients receiving oral erythromycin products.</p>
<p>There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to prevent <span class="product-label-link" type="condition" conceptid="434279" conceptname="Congenital syphilis">congenital syphilis</span>. Infants born to women treated during pregnancy with oral erythromycin for early <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> should be treated with an appropriate penicillin regimen.</p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin. Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels. (See package insert for lovastatin.)</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ERYCÂ Capsules, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_52303DD9-D5E6-447F-87D3-AC5F0F3A46CB"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_59DE2ACB-CF51-4D6D-BB56-1DD3F6782135"></a><a name="section-8.1"></a><p></p>
<h2>General: </h2>
<p class="First">Prescribing ERYC in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Since erythromycin is principally excreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_ID_460722CA-1339-4903-B13B-7B247A980433">CLINICAL PHARMACOLOGY</a></span> and <a href="#i4i_warnings_ID_EB0A3363-9545-4795-8993-D9B0ECDA79CA">WARNINGS</a>)</p>
<p>There have been reports that erythromycin may aggravate the <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, erythromycin should be discontinued and appropriate therapy instituted.</p>
<p>When indicated, incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_7DE9ED58-BBE9-4B68-B1F5-3DCC18DCB0A7"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients: </h2>
<p class="First">Patients should be counseled that antibacterial drugs including ERYC should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ERYC is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ERYC or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_E000AEB4-6C1D-4D6E-8EE6-8F478273BA97"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions: </h2>
<p class="First">Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QTc interval prolongation, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, and other <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, have been observed. (See <a href="#i4i_contraindications_ID_8793A843-1AA9-46D9-AF02-BAABEFF94047">CONTRAINDICATIONS</a>). In addition, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported rarely with concomitant administration of terfenadine and erythromycin.</p>
<p>There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (QT prolongation, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>) most likely due to the inhibition of hepatic metabolism of cisapride by erythromycin.</p>
<p>There has been an isolated report of drug interaction occurring with the concomitant administration of erythromycin and quinidine in their usual oral forms, resulting in QT prolongation, <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Caution and close monitoring is recommended when the drugs are administered concomitantly.</p>
<p>Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase of serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.</p>
<p>Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.</p>
<p>There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to this drug may be more pronounced in the elderly.</p>
<p>Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and dysethesia.</p>
<p>Erythromycin has been reported to decrease the clearance of triazolam and midazolam and, thus, may increase the pharmacologic effect of these benzodiazepines.</p>
<p>The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs. There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, hexobarbital, phenytoin, alfentanil, disopyramide, lovastatin, bromocriptine, valproate, terfenadine and astemizole. Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_ID_A4D3E580-CCB4-4276-ADB5-FF58C0990BA7"></a><a name="section-8.4"></a><p></p>
<h2>Drug/Laboratory test interactions: </h2>
<p class="First">Erythromycin interferes with the fluorometric determination of urinary catecholamines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_D8995F67-8A3F-43E8-BC30-115A17E29EF2"></a><a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility: </h2>
<p class="First">Long-term (2-year) oral studies conducted in rats with erythromycin base did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. There was no apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25 percent of diet.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_B162A70A-6750-4F45-87EA-5D027F14FC28"></a><a name="section-8.6"></a><p></p>
<h2>Pregnancy: Â </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_97366A87-DAE1-447C-9725-616000BE64E9"></a><a name="section-8.6.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category B: </h3>
<p class="First">There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> or any other adverse effect on reproduction in female rats fed erythromycin base (up to 0.25 percent of diet) prior to and during mating, during gestation, and through weaning of two successive litters. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_ID_CD1DE939-B63C-452A-AF88-1EDEEC058D88"></a><a name="section-8.7"></a><p></p>
<h2>Labor and Delivery: </h2>
<p class="First">The effect of erythromycin on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_54A84C13-2CE8-4DE2-A292-117A53331664"></a><a name="section-8.8"></a><p></p>
<h2>Nursing Mothers: </h2>
<p class="First">Erythromycin is excreted in human milk. Caution should be exercised when erythromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_C64F961C-5ECD-4105-B1E9-D2F64E93728D"></a><a name="section-8.9"></a><p></p>
<h2>Pediatric Use: </h2>
<p class="First">See <span class="Bold"><a href="#i4i_indications_ID_37772C48-F39D-489D-BBD8-9934C167EEE8">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#i4i_dosage_admin_ID_9AD34C7D-2278-4B70-856B-9C7DA3FFE491">DOSAGE AND ADMINISTRATION</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_E6B20FDF-7C96-476D-B834-62CD040280E9"></a><a name="section-8.10"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies with ERYC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of the decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>See <span class="Bold"><a href="#i4i_warnings_ID_EB0A3363-9545-4795-8993-D9B0ECDA79CA">WARNINGS</a></span> with regard to prolongation of QT syndrome in geriatric patients with erythromycin products.</p>
<p>Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See<a href="#i4i_precautions_ID_52303DD9-D5E6-447F-87D3-AC5F0F3A46CB">PRECAUTIONS</a>, <a href="#i4i_drug_interaction_ID_E000AEB4-6C1D-4D6E-8EE6-8F478273BA97">Drug Interactions: </a>.)</p>
<p>ERYC 250 mg capsules do not contain sodium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_A4219B03-0ADF-4791-82A4-A2020568177D"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment. (See <a href="#i4i_warnings_ID_EB0A3363-9545-4795-8993-D9B0ECDA79CA">WARNINGS</a>). Symptoms of hepatic dysfunction and/or abnormal liver function test results may occur (See <a href="#i4i_warnings_ID_EB0A3363-9545-4795-8993-D9B0ECDA79CA">WARNINGS</a>).</p>
<p>Rarely, erythromycin has been associated with the production of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, in individuals with prolonged QTc intervals.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> ranging from <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have occurred. <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> ranging from mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span> to <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_6D33AEF6-724B-43CD-AC93-AF08D3991BED"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">In case of overdosage, erythromycin should be discontinued. Overdosage should be handled with the prompt elimination of unabsorbed drug and all other appropriate measures.</p>
<p>Erythromycin is not removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_9AD34C7D-2278-4B70-856B-9C7DA3FFE491"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Erythromycin is well absorbed and may be given without regard to meals. Optimum blood levels are obtained in a fasting state (administration at least one half hour and preferably two hours before or after a meal); however, blood levels obtained upon administration of enteric-coated erythromycin products in the presence of food are still above minimal inhibitory concentrations (MICs) of most organisms for which erythromycin is indicated.</p>
<dl>
<dt>Â </dt>
<dd>ADULTS: The usual dose is 250 mg every 6 hours taken one hour before meals. If twice-a-day dosage is desired, the recommended dose is 500 mg every 12 hours. Dosage may be increased up to 4 grams per day, according to the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Twice-a-day dosing is not recommended when doses larger than 1 gram daily are administered.</dd>
<dt>Â </dt>
<dd>CHILDREN: Age, weight, and severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are important factors in determining the proper dosage. The usual dosage is 30 to 50 mg/kg/day in divided doses. For the treatment of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, this dose may be doubled.</dd>
</dl>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">Streptococcal infections</span>: </span> A therapeutic dosage of oral erythromycin should be administered for at least 10 days. For continuous prophylaxis against recurrences of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> in persons with a history of rheumatic heart disease, the dose is 250 mg twice a day.</p>
<p><span class="Bold">Primary <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>:</span> 30 to 40 grams given in divided doses over a period of 10 to 15 days.</p>
<p><span class="Bold">Intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>:</span> 250 mg four times daily for 10 to 14 days for adults; 30 to 50 mg/kg/day in divided doses for 10 to 14 days for children.</p>
<p><span class="Bold">Legionnairesâ€™ disease:</span> Although optimal doses have not been established, doses utilized in reported clinical data were those recommended above (1 to 4 grams daily in divided doses).</p>
<p><span class="Bold">Urogenital <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> during pregnancy due to <span class="Italics">Chlamydia trachomatis</span>:</span> Although the optimal dose and duration of therapy have not been established, the suggested treatment is erythromycin 500 mg, by mouth, 4 times a day on an empty stomach for at least 7 days. For women who cannot tolerate this regimen, a decreased dose of 250 mg, by mouth, 4 times a day should be used for at least 14 days.</p>
<p>For adults with uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Chlamydia trachomatis</span> in whom tetracyclines are contraindicated or not tolerated: 500 mg, by mouth, 4 times a day for at least 7 days.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span>:</span> Although optimum dosage and duration of therapy have not been established, doses of erythromycin utilized in reported clinical studies were 40 to 50 mg/kg/day, given in divided doses for 5 to 14 days.</p>
<p><span class="Bold">Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> due to <span class="Italics">Ureaplasma urealyticum</span>:</span> When tetracycline is contraindicated or not tolerated: 500 mg of erythromycin, orally, four times daily for at least 7 days.</p>
<p><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> due to <span class="Italics">N gonorrhoeae</span>: </span>500 mg IV of erythromycin lactobionate for injection, USP every 6 hours for 3 days followed by 250 mg of erythromycin, orally every six hours for 7 days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_F05F071D-0CD6-4F50-B4B0-1C14976E251C"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">ERYC<span class="Sup">Â®</span> (Capsule 696), clear and orange opaque capsules, each containing 250 mg erythromycin as enteric-coated pellets, are available as follows:</p>
<p><span class="Bold">N</span> 0430-0696-24 Bottles of 100.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_ID_AA8E1282-149D-452C-A798-BE9D031ADF39"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">STORAGE CONDITIONS: </span></h1>
<p class="First">Store at controlled room temperature 15Â° C to 30Â° C (59Â° F to 86Â° F).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_ID_11CE8AED-CF03-4D2E-9C02-063729A7A8CE"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<ol>
<li><span class="Bold">National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span> â€” Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25, NCCLS, Villanova, PA, December 1993.</span></li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests</span> â€” Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24, NCCLS, Villanova, PA, December 1993.</li>
<li>Committee on <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span>, <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, The American Heart Association<span class="Italics">: Prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">Rheumatic Fever</span></span>. <span class="Bold">Special Report</span><span class="Italics">Circulation</span> 78 (4): 1082-1086, October 1988.</li>
</ol>
<p class="First">Â </p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured by:                                    </p>
<p>Mayne Pharma International Pty Ltd</p>
<p>1538 Main North Road</p>
<p>Salisbury South, South Australia 5106</p>
<p>Marketed by:</p>
<p>Warner Chilcott, Inc.</p>
<p>Rockaway, NJ 07866  </p>
<p>Revised March 2007                                                                                             0696G017 </p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=C3F7CD94-D842-4F6B-A582-A38C751A790A&amp;name=eryc-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERYCÂ 		
					</strong><br><span class="contentTableReg">erythromycin capsule, coated pellets</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0696</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERYTHROMYCIN</strong> (ERYTHROMYCIN) </td>
<td class="formItem"></td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow #6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (ORANGE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Eryc;WC;696</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0696-24</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott (US), LLC</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>D928476A-E895-B3CB-4012-8E502D3C6983</div>
<div>Set id: C3F7CD94-D842-4F6B-A582-A38C751A790A</div>
<div>Version: 2</div>
<div>Effective Time: 20080626</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott (US), LLC</div></p>
</body></html>
